Precision for Medicine, a leading provider of next-generation drug development services, and PathAI, a global leader in digital pathology, announced a strategic collaboration to integrate PathAI’s advanced digital pathology technologies into Precision’s clinical trial and biospecimen operations. The partnership aims to develop novel AI-driven tools to support biomarker discovery, spatial biology, and tissue-based research.

As part of the collaboration, Precision for Medicine will utilize several of PathAI’s technologies, including AISight®, a digital pathology image management system, and a suite of AI-powered algorithms to enhance biospecimen analysis and clinical trial services. These tools will introduce validated, algorithm-based quality control measures to improve data consistency and reliability. Additionally, PathAI’s machine learning models will help optimize Precision’s multimodal datasets, identifying scalable, actionable biomarkers to better interpret complex tissue biology.

"Together, we’re introducing critical quality control into tumor biopsy workflows and applying machine learning early in development to pinpoint biomarkers most relevant for clinical success," said Darren Davis, PhD, Senior Vice President of Global Digital Pathology, Genomics, and Liquid Biopsy Solutions at Precision for Medicine. He emphasized how Precision’s CLIA-certified labs will drive faster, more precise patient stratification and decision-making in clinical trials.

The collaboration enables biopharma clients to access unique imaging workflows integrated within Precision’s laboratory and clinical trial infrastructure. The AI-enhanced services will exclusively be available through Precision for Medicine, offering unmatched customization and integration.

"At PathAI, we aim to harness AI to deepen the accuracy and efficiency of pathology insights," said Andy Beck, MD, PhD, Co-founder and CEO of PathAI. "We are excited to work with Precision for Medicine to bring differentiated value to our clients."

"This collaboration enriches our biospecimen services by adding cellular-level insights to already sequenced samples, advancing biomarker discovery beyond traditional pathology," added Cullen Taylor, MD, Medical Director at Precision for Medicine. "It’s a significant step forward in supporting diagnostic validation and therapeutic development."